130 related articles for article (PubMed ID: 6492486)
1. Study on the striatal dopamine availability in Parkinson's disease.
Indo T
Jpn J Med; 1984 Aug; 23(3):228-36. PubMed ID: 6492486
[TBL] [Abstract][Full Text] [Related]
2. [Striatal dopamine availability in Parkinson's disease--with reference to the wearing-off phenomenon].
Indo T
Rinsho Shinkeigaku; 1984 Oct; 24(10):1008-16. PubMed ID: 6518691
[No Abstract] [Full Text] [Related]
3. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
4. Levodopa and the progression of Parkinson's disease.
Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
[TBL] [Abstract][Full Text] [Related]
5. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
[TBL] [Abstract][Full Text] [Related]
6. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Breck L; Kutt H; McDowell FH
Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
[TBL] [Abstract][Full Text] [Related]
7. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation.
Spencer SE; Wooten GF
Neurology; 1984 Aug; 34(8):1105-8. PubMed ID: 6540390
[TBL] [Abstract][Full Text] [Related]
8. Dopamine receptors in Parkinson's disease.
Hassan MN; Thakar JH
Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(2-3):173-82. PubMed ID: 3290993
[TBL] [Abstract][Full Text] [Related]
9. Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease.
Cedarbaum JM; Olanow CW
Neurology; 1991 Oct; 41(10):1567-70. PubMed ID: 1922797
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease as a model for changes in dopamine receptor dynamics with aging.
Rinne UK
Gerontology; 1982; 28 Suppl 1():35-52. PubMed ID: 7044903
[TBL] [Abstract][Full Text] [Related]
12. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.
Innis RB; Marek KL; Sheff K; Zoghbi S; Castronuovo J; Feigin A; Seibyl JP
Mov Disord; 1999 May; 14(3):436-42. PubMed ID: 10348466
[TBL] [Abstract][Full Text] [Related]
13. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
Roberts JW; Cora-Locatelli G; Bravi D; Amantea MA; Mouradian MM; Chase TN
Neurology; 1993 Dec; 43(12):2685-8. PubMed ID: 8255478
[TBL] [Abstract][Full Text] [Related]
14. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations.
Kempster PA; Gibb WR; Stern GM; Lees AJ
J Neurol Neurosurg Psychiatry; 1989 Jan; 52(1):72-6. PubMed ID: 2709038
[TBL] [Abstract][Full Text] [Related]
15. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN
Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
[TBL] [Abstract][Full Text] [Related]
16. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Chase TN
Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
[TBL] [Abstract][Full Text] [Related]
17. Pathogenetic studies of motor fluctuations in Parkinson's disease.
Chase TN; Mouradian MM; Fabbrini G; Juncos JL
J Neural Transm Suppl; 1988; 27():3-10. PubMed ID: 3042912
[TBL] [Abstract][Full Text] [Related]
18. Levodopa/carbidopa/entacapone in Parkinson's disease.
Seeberger LC; Hauser RA
Expert Rev Neurother; 2009 Jul; 9(7):929-40. PubMed ID: 19589043
[TBL] [Abstract][Full Text] [Related]
19. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.
Leenders KL; Palmer AJ; Quinn N; Clark JC; Firnau G; Garnett ES; Nahmias C; Jones T; Marsden CD
J Neurol Neurosurg Psychiatry; 1986 Aug; 49(8):853-60. PubMed ID: 3091770
[TBL] [Abstract][Full Text] [Related]
20. [L-dopa therapy of parkinson syndrome].
Kapfhammer HP; Kuss HJ; Rüther E
Nervenarzt; 1985 Feb; 56(2):57-68. PubMed ID: 3920542
[No Abstract] [Full Text] [Related]
[Next] [New Search]
